Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03691376
Title Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications

ovary epithelial cancer

peritoneal carcinoma

fallopian tube carcinoma

Therapies

Melphalan

NY-ESO-1 TCR CD4- CD34+ HSC

Aldesleukin

Autologous NY-ESO-1-specific CD8-positive T cells

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.